Borjigin J, Nathans J
Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):337-41. doi: 10.1073/pnas.90.1.337.
Bovine pancreatic trypsin inhibitor (BPTI) binds to trypsin and anhydrotrypsin (an enzymatically inactive derivative of trypsin) with affinities of 6 x 10(-14) and 1.1 x 10(-13) M, respectively. We have taken advantage of the high affinity and specificity of this binding reaction to develop a protein tagging system in which biotinylated trypsin or biotinylated anhydrotrypsin is used as the reagent to detect recombinant fusion proteins into which BPTI has been inserted. Two proteins, opsin and growth hormone, were used as targets for insertional mutagenesis with BPTI. In each case, both domains of the fusion protein appear to be correctly folded. The fusion proteins can be specifically and efficiently detected by biotinylated trypsin or biotinylated anhydrotrypsin, as demonstrated by staining of transfected cells, protein blotting, affinity purification, and a mobility shift assay in SDS/polyacrylamide gels.
牛胰蛋白酶抑制剂(BPTI)与胰蛋白酶和脱水胰蛋白酶(胰蛋白酶的一种无酶活性衍生物)结合,其亲和力分别为6×10⁻¹⁴和1.1×10⁻¹³M。我们利用这种结合反应的高亲和力和特异性开发了一种蛋白质标记系统,其中生物素化的胰蛋白酶或生物素化的脱水胰蛋白酶用作试剂来检测已插入BPTI的重组融合蛋白。视蛋白和生长激素这两种蛋白质被用作BPTI插入诱变的靶标。在每种情况下,融合蛋白的两个结构域似乎都正确折叠。如转染细胞染色、蛋白质印迹、亲和纯化以及SDS/聚丙烯酰胺凝胶中的迁移率变动分析所示,融合蛋白可以被生物素化的胰蛋白酶或生物素化的脱水胰蛋白酶特异性且高效地检测到。